Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives.: A new class of selective GSK-3 inhibitors

被引:152
作者
Olesen, PH [1 ]
Sorensen, AR [1 ]
Urso, B [1 ]
Kurtzhals, P [1 ]
Bowler, AN [1 ]
Ehrbar, U [1 ]
Hansen, BF [1 ]
机构
[1] Novo Nordisk AS, Discovery, DK-2760 Malov, Denmark
关键词
D O I
10.1021/jm021095d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel class of GSK-3 inhibitors with favorable water solubility was identified in a HTS screen. SAR studies identified bioisosteric structural moieties in this class of compounds. The compounds were tested in a GSK-3 inhibition assay at 100 muM ATP giving IC50's in the range from 0.1 to 10 muM. The compounds are ATP competitive inhibitors. They modulate glycogen metabolism and stimulate the accumulation of intracellular beta-catenin in whole cell assays with EC50's in the range from 2 to 18 muM and 4.5-44 muM, respectively. For selected compounds, only a 10-fold lower potency was obtained in cellular assays compared to the potency obtained for inhibition of the isolated enzyme, reflecting a good cell permeability of this compound class. At 10 muM of test compound a Mold stimulation of the glycogen synthesis in rat soleus muscle was obtained compared to the level of glycogen synthesis observed at 0.2 nM insulin. This stimulation of glycogen synthesis is comparable to the maximal stimulation by insulin itself.
引用
收藏
页码:3333 / 3341
页数:9
相关论文
共 23 条
[1]   Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? [J].
Anderton, BH ;
Dayanandan, R ;
Killick, R ;
Lovestone, S .
MOLECULAR MEDICINE TODAY, 2000, 6 (02) :54-59
[2]  
BOWLER AN, 2001, 11 RSC SCI MED CHEM
[3]   Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats [J].
Cline, GW ;
Johnson, K ;
Regittnig, W ;
Perret, P ;
Tozzo, E ;
Xiao, L ;
Damico, C ;
Shulman, GI .
DIABETES, 2002, 51 (10) :2903-2910
[4]   Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription [J].
Coghlan, MP ;
Culbert, AA ;
Cross, DAE ;
Corcoran, SL ;
Yates, JW ;
Pearce, NJ ;
Rausch, OL ;
Murphy, GJ ;
Carter, PS ;
Cox, LR ;
Mills, D ;
Brown, MJ ;
Haigh, D ;
Ward, RW ;
Smith, DG ;
Murray, KJ ;
Reith, AD ;
Holder, JC .
CHEMISTRY & BIOLOGY, 2000, 7 (10) :793-803
[5]   The renaissance of GSK3 [J].
Cohen, P ;
Frame, S .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (10) :769-776
[6]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[7]   Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice [J].
Eldar-Finkelman, H ;
Schreyer, SA ;
Shinohara, MM ;
LeBoeuf, RC ;
Krebs, EG .
DIABETES, 1999, 48 (08) :1662-1666
[8]   Glycogen synthase kinase 3: an emerging therapeutic target [J].
Eldar-Finkelman, H .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (03) :126-132
[9]   PROTEIN KINASES .6. THE EUKARYOTIC PROTEIN-KINASE SUPERFAMILY - KINASE (CATALYTIC) DOMAIN-STRUCTURE AND CLASSIFICATION [J].
HANKS, SK ;
HUNTER, T .
FASEB JOURNAL, 1995, 9 (08) :576-596
[10]  
Hansen BF, 1996, BIOCHEM J, V315, P271